title: Evaluation of 451 Danish boys with delayed puberty: diagnostic use of a new puberty nomogram and effects of oral testosterone therapy.
abstract: BACKGROUND
  Few data exist on the diagnostic criteria, and on the effects of puberty induction, in boys with constitutional delay in growth and puberty (CDGP).
  
  
  OBJECTIVE
  To develop puberty nomograms based on Danish boys with normal pubertal development. To evaluate the different diagnostic criteria and the effect of oral testosterone undecanoate (TU) in boys with CDGP.
  
  
  METHODS
  A cross-sectional and longitudinal study of Danish boys with normal pubertal development (COPENHAGEN puberty study). A retrospective observational study of 451 boys evaluated for delayed puberty between 1990 and 2013.
  
  
  METHODS
  Tertiary referral center for pediatric endocrinology.
  
  
  METHODS
  One hundred and sixty-four (36%) boys evaluated for CDGP were excluded due to missing data, reclassification, or associated comorbidities, yielding 287 (64%) eligible for analysis.
  
  
  METHODS
  The number of patients with CDGP classified by the puberty nomogram (genital stage < -2 SD for age) versus the classical criteria (genital stage 1 at ≥ 14 years). The effect of one year of oral TU treatment on pubertal progression, circulating hormones, height, and predicted adult height (PAH).
  
  
  RESULTS
  Seventy-eight (27%) of the 287 boys had delayed pubertal onset according to the classical criteria, whereas 173 (60%) of the 287 boys had impaired pubertal progression according to the puberty nomogram. Ninety-six (56%) of these 173 boys were treated with oral TU for 0.8 years (0.5; 1.3) [median (25th; 75th percentiles)], which resulted in beneficial effects on pubertal progression. Height increased from -1.9 SD (-2.5; -1.2) to -1.5 SD (-2.1; -0.7) (P < .001), and PAH increased from 172.3 cm (170.3; 182.8) to 178.1 cm (171.4; 191.7) (P = .001) following one year of treatment.
  
  
  CONCLUSIONS
  The puberty nomogram evaluates both delayed pubertal onset as well as delayed pubertal progression and allows separation of normal versus abnormal pubertal development. Oral TU treatment was followed by pubertal induction and progression and short-term growth without compromising final height.
authors.affiliation: Department of Growth and Reproduction and EDMaRC (J.G.L., C.P.H., M.G.M., M.B.J., A.J.), Rigshospitalet, University of Copenhagen, Denmark; Department of Biostatistics (J.H.P.), University of Copenhagen, Denmark.
authors.forename: Jacob Gerner
authors.initials: JG
authors.lastname: Lawaetz
authors.forename: Casper P
authors.initials: CP
authors.lastname: Hagen
authors.forename: Mikkel Grunnet
authors.initials: MG
authors.lastname: Mieritz
authors.forename: Martin
authors.initials: M
authors.lastname: Blomberg Jensen
authors.forename: Jørgen Holm
authors.initials: JH
authors.lastname: Petersen
authors.forename: Anders
authors.initials: A
authors.lastname: Juul
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D001827:Body Height / Q000187:drug effects; D002648:Child; D003430:Cross-Sectional Studies; D003718:Denmark / Q000453:epidemiology; D057238:Growth Charts; D020249:Hormone Replacement Therapy / Q000379:methods; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D049451:Nomograms; D011627:Puberty / Q000502:physiology; D011628:Puberty, Delayed / Q000175:diagnosis* / Q000188:drug therapy* / Q000453:epidemiology; D012189:Retrospective Studies; D013739:Testosterone / Q000008:administration & dosage*; D055815:Young Adult
chemical_list: D013739:Testosterone